Key result
Emerging biomarkers such as BNP, NGAL, and KIM-1 may improve early detection, differential diagnosis, and prognostic assessment in patients with acute cardiorenal syndrome type I.
Why the study?
Do emerging biomarkers improve early detection, differential diagnosis, and prognostic assessment in patients with acute cardiorenal syndrome compared to traditional markers?
Do emerging biomarkers improve early detection, differential diagnosis, and prognostic assessment in patients with acute cardiorenal syndrome compared to traditional markers?
Emerging biomarkers offer potential advantages over traditional markers like serum creatinine for the early detection and management of acute cardiorenal syndrome.
Answers are grounded in this paper and cite their sources.
Does not yet support routine use over creatinine in acute cardiorenal syndrome; leaves open prospective validation before practice change.
Cardiorenal syndromes are disorders of the heart and kidneys whereby dysfunction in one organ may lead to dysfunction in the other organ. Cardiorenal syndrome type I (CRS I) is defined as acute kidney injury caused by acute cardiac dysfunction such as acute decompensated heart failure and acute coronary syndrome. Traditional markers like serum creatinine may delay the diagnosis of acute kidney injury and provide limited information regarding the underlying pathophysiology in the setting of CRS I. Herein, we briefly review some emerging biomarkers, including brain natriuretic peptide, soluble ST2, angiopoietin, soluble thrombomodulin, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C, interleukin-18 and calprotectin. These biomarkers may help early detecting, differential diagnosis, assessing disease severity and prognosis in patients with CRS I, therefore improve patient management and outcomes.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2018) conducted a review in Cardiorenal syndrome type I (CRS I). Emerging biomarkers (e.g., BNP, soluble ST2, NGAL, KIM-1) vs. Traditional markers (e.g., serum creatinine) was evaluated. Emerging biomarkers such as BNP, NGAL, and KIM-1 may improve early detection, differential diagnosis, and prognostic assessment in patients with acute cardiorenal syndrome type I.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: